New vaccine aims to fight breast cancer by training the immune system
NCT ID NCT04270149
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a vaccine made from estrogen receptor peptides, combined with immune boosters, in 8 people with ER-positive breast cancer who have completed standard therapy. The goal is to see if the vaccine is safe and can trigger an immune response against cancer cells. It may help prevent recurrence in patients with higher-risk disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?